Valuation: CSL Limited

Market Cap 4.09TCr 3.58TCr 3.3TCr 3.05TCr 5.79TCr 3,90400Cr 5.89TCr 39TCr 15TCr 1,92300Cr 15TCr 15TCr 6,61200Cr P/E 2026 *
-46x
P/E 2027 * 28.5x
Enterprise Value 4.98TCr 4.35TCr 4.02TCr 3.71TCr 7.04TCr 4,74800Cr 7.16TCr 48TCr 19TCr 2,33900Cr 19TCr 18TCr 8,04100Cr EV / Sales 2026 *
3.23x
EV / Sales 2027 * 3.13x
Free-Float
99.3%
Yield 2026 *
3.34%
Yield 2027 * 3.42%
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.51%+1.57%+18.72%-5.52% 6.76TCr
-5.16%-8.63%+37.37%+202.27% 5.16TCr
+5.28%+39.50%+39.50%+39.50% 4.3TCr
-10.83%-14.41%+99.15%-44.54% 2.71TCr
+0.12%-7.85%+47.16%-29.27% 2.94TCr
-1.53%-0.13%+65.92%+88.58% 2.33TCr
+3.88%+2.16%+11.78%+201.51% 1.99TCr
-4.75%+11.27%+85.63%+394.76% 1.68TCr
-1.59%-1.63%+61.04%+130.75% 1.69TCr
Average -1.68%-1.87%+51.81%+108.67% 3.29TCr
Weighted average by Cap. -1.45%-2.55%+44.68%+83.29%

Financials

2026 *2027 *
Net sales 1.54TCr 1.35TCr 1.24TCr 1.15TCr 2.18TCr 1,46800Cr 2.21TCr 15TCr 5.83TCr 72TCr 5.78TCr 5.65TCr 2,48600Cr 1.56TCr 1.37TCr 1.26TCr 1.17TCr 2.21TCr 1,49100Cr 2.25TCr 15TCr 5.92TCr 73TCr 5.87TCr 5.74TCr 2,52500Cr
Net income -89Cr -78Cr -72Cr -67Cr -126.34Cr -8.52TCr -128.47Cr -861.38Cr -338.27Cr -4.2TCr -335.51Cr -328.2Cr -14TCr 118.32Cr 103.49Cr 95Cr 88Cr 167.29Cr 11TCr 170.11Cr 1.14TCr 447.91Cr 5.56TCr 444.25Cr 434.59Cr 19TCr
Net Debt 884.94Cr 774.06Cr 713.97Cr 659.43Cr 1.25TCr 84TCr 1.27TCr 8.53TCr 3.35TCr 42TCr 3.32TCr 3.25TCr 1,42900Cr 807.02Cr 705.9Cr 651.1Cr 601.36Cr 1.14TCr 77TCr 1.16TCr 7.78TCr 3.06TCr 38TCr 3.03TCr 2.96TCr 1,30400Cr
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-